Emergpharma`s chinese diabetes pharmaceutical market

863 views

Published on

Chinese Diabetes Pharmaceutical Market surpassed USD 3 bn in 2012 and is expected to achieve 7bn in 2007. according to Emergpharma's latest report presented yesterday. It is one of the fastest growth segment in the Global Pharmaceutical Market. Novo Nordisk, Bayer and Sanofi dominates this market with more than 50%.

Published in: Business, Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
863
On SlideShare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
32
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Emergpharma`s chinese diabetes pharmaceutical market

  1. 1. Chinese Diabetes Pharmaceutical Market August 2013
  2. 2.  19 Chapters (165 pages) analyzing  Epidemiology,  Pool of treated patients  Market dynamics  Market segmentation by type of treatment, family of products, products, marketers and affordability  Market players and their strategies  Health Economics in China  Impact of the reform in diabetes treatment  The reimbursement system and its impact on diabetes market  Market forecast 2013-2017  72 explanatory charts, tables and figures to facilitate key success factors understanding and save time  Directed and written by the reputed expert in emerging pharmaceutical markets and Head of Emergphama`s Business Intelligence Unit Jose I. Díaz Emergpharma, consulting company founded in 2008 and specialized in pharmaceutical emerging markets is launching its “Chinese Diabetes Pharmaceutical Market Report Outcomes 2013-2017”
  3. 3. – Why Glucobay keeps its position as OAD market leader despite new generation products availability and despite in most developed markets Glucobay failed to become a big player. Why it is expected to remain at least two more years as market leader – Why Insulin market is expected to grow faster in China than in other markets, driving the market to even higher levels of growth – Why, despite what happens in other segments, MNC’s (multinationals) dominate the diabetes market in China – Why although it has been estimated in USD 7 bn the diabetes pharmaceutical market size in 2007, it would achieve 8 or even 9 million if some favorable conditions happens simultaneously. – Why companies like West Pharmaceutical and other delivery suppliers have an important path to grow in China in the shadows of big Pharmaceuticals – Where big/middle sized Asian Pharmaceutical Companies have an interesting and profitable segment to gain market share – What is a wise strategy for second or third comers to market in diabetes China market Some issues addressed in the “Chinese Diabetes Pharmaceutical Market Report, Outcomes 2013-2017”:
  4. 4. Chinese Diabetes Pharmaceutical Market Slides Sample
  5. 5. Chinese diabetes market: a fast growing segment 3% 5% 12% 18% 27% Developed Markets World Market Average APAC China Chinese diabetes market Growth Forecast Different Pharmaceutical Segments 2013-2017 • The diabetes market in China is expected to grow over the Pharmaceutical Market average in the country and is positioned as one of the fastest Pharmaceutical Market Segments Worldwide • In 2012 the market exceeded USD 3 bn and is expected to achieve USD 7 bn in 2017 • Insulins segment, growing above 30% CAGR in the period 2007-2012 have surpassed by first time the non insulin market segment in size and is expected to keep its position as market driver with higher growth level than non insulin drugs between 2013 and 2017 Source: Emergpharma`s model
  6. 6. Market Drivers Why this market is expected to more than double sales in 5 years Epidemiology & treated patients Increase on the prevalence of diabetes as consequence of more urban population and lifestyle changes Increase on the number of treated patients due to more awareness on diabetes implications Socio-Healthcare Economics GDp per capita and Healthcare Expenses per capita increase, growth of urban middle class Diabetes healthcare expenses growth and increase of its participation in Healtcare Budget Trends and new product availability Increased use of combined therapy and FDC in particular Trend to treat early and more aggresively New drugs available (incretin market) Increased use of insulin analogs and devices
  7. 7. Diabetes Market Changes 2012-2017 USD(x000.000) 3,000 7,000800 1,000 2,700 -500 - 1,000 2,000 3,000 4,000 5,000 6,000 7,000 8,000 Market2012 Incr.Nr.patients Incr.Nr.ofdrug/patient Incr.Tr.cost/patient PriceCuts Market2017
  8. 8. Epidemiology of diabetes in China • In addition to 92 million of diabetics, 140 million people are living with IGT (Impaired Glucose Tolerance) • The number of diabetics living in China is expected to achieve 130 million in 2030 • Although 85-90% of diagnosed patients are on treatment, diagnose rates are still low compared with developed countries 371,778 92,285 38,058 32,349 Patients with Diabetes in the World Patients with Diabetes in China Patients diagnosed with diabetes in China Patients on treatment for diabetes in China Data 2012 (x000) 24 49 92 130 0 50 100 150 2000 2010 2012 2030 E Diabetic adults in China Source: IDF and World Bank
  9. 9. Diabetes Treatment in China • Among diagnosed patients, 10% are on diet and exercise and 15% are not treated • 15% of the 16 million patients treated on monotherapy are receiving only Traditional Chinese Medicine (TCM) • Also 10% of patients treated in combined non insulin therapy were receiving TCM + conventional treatment • In total, from 92 million living with diabetes in China, lesss than 27 million are receiving at least one conventional drug, while 65 million are not diagnosed, not treated, treated on diet and exercise or with traditional medicinal chinese herbal products • Only 11% of diabetics in China achieve targets according to international guidelines 54,227 5,709 3,235 16,175 8,087 3,882 970 Diabetes Patients China 2012 (x000) Undiagnosed Diagnosed but Untreated Diet and Exercise Monotherapy Combined non insulin Insulin Alone Insulin combined Source: Emergpharma`s model
  10. 10. Differences in treatment costs • The upper 5% of patients whose treatment was on average above 500 $ per year represent 36% of the total value of the market • The second category including 20% of patient on treatment represents slightly less, 33% of all • The lowest category, including 75% of all patients represents in monetary terms just 31% Patient treated more than 500 US $, 1,391 Patient treated from 100 to 500 $, 5,810 Patient treated less than 100 $, 21,268 Patient Segments by yearly cost of treatment (x000) More than 500$ 36% 100-500 $ 33% < 100 $ 31% Segment Sizes % Values Every 1% of patients on monotherapy with old products switching to dpp4 would represent aprox 300 million extra sales (10% of diabetes market in 2012) Source: Emergpharma`s model
  11. 11. Diab-market Monotherapy Dynamics 2012 16.000.000 patients Diet and Exercise New diagnosed (Disease Progression) Combination Insulin +2.000.000 / year -1.650.000 / year Among 16 million patients in monotherapy, only 3.65 million are expected to change treatment per year Switch to other monotherapy < 5% Source: Emergpharma`s model
  12. 12. Non insulin Market (values) • Contrary to other markets, in China Glucobay (acarbose) is market leader in the non insulins • 89% of non insulin products are “old generation” will many generics in the market, while new families represent less than 10% • It is expected that the situation will change in the forthcoming years with an important penetration of Dpp4 • TZDs are reducing their market share due to the important safety concerns experienced worldwide, Avandia family in particular Biguanides 16% Alfa glucosidase 40%Glinides 17% Sulfonil ureas 16% TZDs 6% increatin (Dpp4, GLP -1) 2% Natural Med 3% Source: Emergpharma`s model based on IMS data, Sanofi and Novo Nordisk published data and Emergpharma`s patient flow
  13. 13. Diabetes Product Market Leaders 2012 (Values) • Six products represent 2/3 of all market sales • Among them, 4 are manufactured by the market leader Novo • Among the 3 insulin market leaders, Lantus and Novomix are comparatively expensive products, and both are growing above the market, near 30% in 2012 • In the forecasted scenario, Novorapid and Levemir will surpase the 100 million $ sales in the next 3-4 years • The incretin market (GLP-1 agonists and DPP4 agonists) grew nearly 70% in 2012 and is expected to grow even more in 2013-2017 fueled by new products availability and stronger penetration of Januvia and Victoza Rest of products 37% Novo Human Insulin 17% Glucobay 16% Novomix 9% Lantus 8% Novonorm 7% Glucophag e 6% Source: Emergpharma`s model based on IMS data, Sanofi and Novo Nordisk published data and Emergpharma`s patient flow
  14. 14. The Healthcare Reform in China • Chinese Government invested USD 180 billion in healthcare improvements between 2009 and 2011 • More than 95% of citizens now have some form of healthcare coverage and the government hast turned to improving the coverage for major diseases • The government is turning to cost containment at many levels to balance the healthcare budget • The current Essential Drug List (EDL) has been expanded to 497 drugs this year (2013). However, only old diabetes products are included in this list Basic healthcare To all citizens Improved basic medical infrastructure Expansion of public haelth serivice programs Separated hospital supervision and remove drug mark up Expansion of medical insurance coverage Establishment of a National Essential Drug List Source: Novo Nordisk presentation to investors April 2013
  15. 15. Chinese Diabetes Pharmaceutical Market A unique tool to understand one of the fastest growth segments on the Global Pharmaceutical Market
  16. 16. Reasons to buy 1. The opportunity – Updated information including data collected in 2013 2. The methodology – Use of mathematic model and Montecarlo simulations to assess outcomes consistency 3. The company – Use of Emergpharmalinks, a network with more than 16.000 executives on the Pharmaceutical Industry to verify and expand information 4. The author – More than 20 years experience in the Pharmaceutical Industry, broad experience in emerging and diabetes markets 5. Report structure – Four different presentations to assess different target needs 6. Report presentation and reimbursement warranty – A 30` free of charge presentation by Videoconference is available at request – Company reimbursement warranty in case the report doesn`t meet promised quality standards
  17. 17. •Emergpharma is a worldwide operating company founded in 2008 specialized in strategic consulting services for pharmaceutical companies with special focus on Emerging Markets. •Our highly specialized network Emergpharmalinks ensures a direct contact with more than 16.000 executives in 102 countries, covering from global and local general management to a broad range of senior executives of pharmaceutical, medical devices, distributor and biotech companies as well as most reputed executive search companies in the world. •Emergpharma Business Intelligence is a highly specialized division delivering strategic analysis and market research on/about companies, geographies and market segments within the Global Pharmaceutical Emerging Market. Jose I. Diaz has developed his professional career in market research, commercial and marketing international operations in the Pharmaceutical Industry. He participated as Marketing Director in the launch of Amaryl M, Lantus and Apidra in many Asian and Latin American countries as part of the Intercontinental Team in Sanofi- Aventis. Emergpharmalinks Professional Network +16.000 executives As consultant expert he has worked for some of the leading companies in diabetes, infectious diseases and cardiovascular: GKS, Roche, Merck and Abbott among others.
  18. 18. Report`s Methodology Epidemiology • Diabetic people in China • Patients on treatment Patients flow • Type of therapy (diet/exercise, TCM,mono, combo, insulin) • Market Dynamics (initiation/add –on/switch) Product sales • Product Market Share • Unitary Costs • Lost of treatment Forecast model • Epidemiology data from International Sources • Treatment growth based on last years trend • Growth by segment based on trends and addition of new comers • Secondary analysis of Health Expenditures to show consistency • Epidemiology data of prevalence were obtained from NEJM 2011 (used by IDF and Word Bank) • Split of patients by type of treatment has been modeled to meet consistency parameters using published statistics as approximate initial sources and building the final ones by Montecarlo simulations • Product shares have been taken from published and internal reports • Treatment costs has been taken from published and in-company reports • Lost of yearly treatment (lack of compliance or adherence…) in the model has been adjusted using data from other similar surveys (15%-20%) • The mathematic model outcomes have shown consistency with Companies published results in more than 90% • Forecasted diabetes market has been double checked with a global analysis of health expenditures evolution and feasible trends showing a remarkable level of consistency.
  19. 19. Report Structure • Because same information may not be equally relevant for every reader, we have designed Emergpharma`s Chinese Diabetes Market Report in four complementary formats: – Full text: for those who need a complete description of methodology, terminology and will be interested to “go in depth” on the data. In total, 19 complete chapters covering specific topics with 72 charts and figures – Bookxecutive: only 20 pages summary for those who can dedicate one hour to get the most relevant elements. – Slide Basics: the core findings in 25 selected slides with comment for those who may require preparing a visual presentation and valuate time savings – Executive summary: 50 top findings in just 4 pages, for a short briefing or a 5 minutes conversation in the elevator.
  20. 20. Chapters 1. Executive Summary 2. Market Definition 3. Methodology and mathematic model 4. Diabetes Epidemiology 5. Diabetes Patients Universe 6. Socio-Health-Economic Environment in China and its impact in diabetes care 7. Chinese pharmaceutical market overview 8. Chinese diabetes market I: Overall environment 9. Chinese diabetes market II: Growth Drivers 10. Chinese diabetes market III: Treatment. Patients segments 11. Chinese diabetes market IV: Market Dynamics 12.Chinese diabetes market V: Products 13. Chinese diabetes market VI: Last Stage Pipeline 14. Chinese diabetes market VII: Players (MNC’s and Local) 15. Chinese diabetes market VIII: Prescribers 16.Chinese diabetes market VIII: Market Segments by cost of treatment 17.Chinese diabetes market IX: Diabetes in the Chinese Healthcare System 18. Chinese diabetes market X: Market Forecast 19. Conclusions 20. Sources / References 21. Figures and charts
  21. 21. Price & Purchase Conditions • The price for the 4 versions (Bookxecutive, Slides Presentation, Executive Summary and Full text) of the report are: – Single copy (pdf+USB): USD 2.499 – Multiple users copy: USD 7.000 • A VC presentation free of charge is available on demand. Please write to: – Ignacio.diaz@emergpharma.es • A Reimbursement Warranty is applicable if the Report doesn`t meet promised outcome and quality • Special discount are available for students and non-profit organizations. Please ask for your personal conditions
  22. 22. Contact Details Please, ask for a copy of contents and characteristics of this report: • By email: – Ignacio.diaz@emergpharma.es • By telephone – Mobile +66 832099048 (Thailand) • By skype (with previous appointment) – Ignacio.diaz2908 • Company website: – www.emergpharma.com

×